Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

132 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of EQ-5D scores among anthracycline-containing regimens followed by taxane and taxane-only regimens for node-positive breast cancer patients after surgery: the N-SAS BC 02 trial.
Shiroiwa T, Fukuda T, Shimozuma K, Kuranami M, Suemasu K, Ohashi Y, Watanabe T. Shiroiwa T, et al. Among authors: shimozuma k. Value Health. 2011 Jul-Aug;14(5):746-51. doi: 10.1016/j.jval.2011.01.007. Epub 2011 Jun 2. Value Health. 2011. PMID: 21839414 Free article. Clinical Trial.
Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial.
Shiroiwa T, Fukuda T, Shimozuma K, Mouri M, Hagiwara Y, Doihara H, Akabane H, Kashiwaba M, Watanabe T, Ohashi Y, Mukai H. Shiroiwa T, et al. Among authors: shimozuma k. Qual Life Res. 2017 Feb;26(2):445-453. doi: 10.1007/s11136-016-1388-1. Epub 2016 Aug 12. Qual Life Res. 2017. PMID: 27517267 Free PMC article. Clinical Trial.
Impact of Adverse Events on Health Utility and Health-Related Quality of Life in Patients Receiving First-Line Chemotherapy for Metastatic Breast Cancer: Results from the SELECT BC Study.
Hagiwara Y, Shiroiwa T, Shimozuma K, Kawahara T, Uemura Y, Watanabe T, Taira N, Fukuda T, Ohashi Y, Mukai H. Hagiwara Y, et al. Among authors: shimozuma k. Pharmacoeconomics. 2018 Feb;36(2):215-223. doi: 10.1007/s40273-017-0580-7. Pharmacoeconomics. 2018. PMID: 29043567 Free PMC article. Clinical Trial.
Factors contributing to the ceiling effect of the EQ-5D-5L: an analysis of patients with prostate cancer judged "no-problems".
Murasawa H, Sugiyama T, Matsuoka Y, Okabe T, Wakumoto Y, Tanaka N, Sugimoto M, Oyama M, Fujimoto K, Horie S, Funagoshi M, Arakawa I, Noto S, Shimozuma K. Murasawa H, et al. Among authors: shimozuma k. Qual Life Res. 2020 Mar;29(3):755-763. doi: 10.1007/s11136-019-02316-4. Epub 2019 Oct 3. Qual Life Res. 2020. PMID: 31583618 Free PMC article.
Response Shift-Adjusted Treatment Effect on Health-Related Quality of Life in a Randomized Controlled Trial of Taxane Versus S-1 for Metastatic Breast Cancer: Structural Equation Modeling.
Murata T, Suzukamo Y, Shiroiwa T, Taira N, Shimozuma K, Ohashi Y, Mukai H. Murata T, et al. Among authors: shimozuma k. Value Health. 2020 Jun;23(6):768-774. doi: 10.1016/j.jval.2020.02.003. Epub 2020 May 17. Value Health. 2020. PMID: 32540235 Free article. Clinical Trial.
132 results